RERegeneron Pharmaceuticals REGN · NASDAQ
$818.77 +0.68% (+$5.50)
- Market cap
- $84.3B
- Enterprise value
- $83.8B
- P/E
- 19.5x
- Forward P/E
- 13.2x
- PEG
- 8.9x
- P/S
- 5.4x
- P/FCF
- 23.9x
- EV/EBITDA
- 14.6x
- ROIC
- 9.2%
- Gross margin
- 84.9%
- Net margin
- 27.9%
- Dividend yield
- 0.45%
- Payout ratio
- 8.8%
- Net debt/EBITDA
- -0.1x
- Beta
- 0.24
- Free float
- 96.2%
About the company
Regeneron Pharmaceuticals (REGN) is an American biotechnology company specializing in the development and production of drugs for the treatment of serious diseases. With a broad portfolio of medicinal products, such as Eylea and Dupixent, Regeneron Pharmaceuticals is one of the leading players in the biotechnology sector. The company is known for its emphasis on scientific research and innovation, allowing it to bring groundbreaking treatments to market. Regeneron Pharmaceuticals is also involved in partnerships with other pharmaceutical companies and academic institutions to expand its research and development capabilities. Regeneron Pharmaceuticals (REGN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and scientific research.
Sector
Healthcare
Industry
Biotechnology
CEO
Leonard S. Schleifer
Employees
15,410
Headquarters
Tarrytown
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 23% this fiscal year.
- What to watch: Revenue growth is slowing: 5.6% a year over the last 3 years against 11% over 5 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 28 USD is left as net profit.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $2.46B against $1.99B.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number